|
News
2008-09 – 2007 – 2006 – 2005
June 24, 2009:
AMORFIX Test for vCJD Acheives 100% specificity on 20,000 blood donations in France
Download the PDF
June 17, 2009:
Amorfix Licenses Novel Theranostic Platform - PROMIS™
Download the PDF
June 11, 2009:
Amorfix Anounces 2009 Year End Results
Download the PDF
May 20, 2009:
Blood Transfusion Service in France Completes 20,000 Tests and Establishes Amorfix EP-vCJD™ Test in a Second Blood Center
Download the PDF
April 29, 2009
Amorfix Closes $3.3 Million Private Placement
Amorfix Life Sciences Ltd. announced today that it has closed a non-brokered private placement, pursuant to which a total of 5,146,300 units (Units) were issued at a price of $0.65 per Unit for gross proceeds of $3,345,095. The size of the offering was increased from the amount previously announced to accommodate oversubscriptions. More
April 24, 2009
Amorfix Announces Private Placement
Amorfix Life Sciences Ltd., a company focused on treatments and diagnostics for misfolded protein diseases, today announced an offering of up to $3 million in units (Units) on a non-brokered private placement basis. More
April 23, 2009
Amorfix and BioMosaics Collaborate to Develop a Blood Test for Liver Cancer Supported by Grant from the Ontario Institute for Cancer Research
Amorfix Life Sciences Ltd. and BioMosaics Inc. today announced a collaboration to develop and commercialize a blood-based assay for early detection of hepatocellular carcinoma or primary liver cancer. This effort is possible due to an "Intellectual Property Development and Commercialization Program" investment of $280,000 from the Ontario Institute for Cancer Research to Sunnybrook Research Institute at Sunnybrook Health Sciences Centre. The collaboration incorporates existing technology for the blood test licensed to BioMosaics, plus new material from SRI needed to improve the test, to be used for assay development at Amorfix. Pending successful development, the product will be commercialized by BioMosaics through its existing distribution network. More
April 20, 2009
Amorfix Corporate Update: AMF Expands Diagnostic and Therapeutic Focus to Include Misfolded Protein Diseases Including Cancer
Amorfix Life Sciences (TSX:AMF), a company focused on treatments and diagnostics for misfolded protein diseases wishes to outline its six (6) product development programs.
“Our vCJD test is being used in feasibility testing by the national blood transfusion service in France and our antibodies and vaccines for ALS have shown prolongation of life in preclinical studies,” said Dr. George Adams, CEO of Amorfix. “With this success, it is time to expand our focus and apply our expertise to more misfolded protein diseases.” More
February 20, 2009
Amorfix Extends Warrant Term by One Year
Amorfix Life Sciences Ltd. announced that it has extended by one year the term of 4,462,521 common share purchase warrants (the "Warrants"), which are exercisable for one common share of Amorfix at an exercise price of $1.95 and were issued on March 8, 2007 as part of a private placement. More
February 11, 2009
Amorfix Announces Fiscal 2009 Third Quarter Results
Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced its operational and financial results for the three and nine months ended December 31, 2008. More
January 20, 2009
Amorfix Awarded “Life Science Company of the Year ” for Moving Innovative Products into Commercialization
Amorfix Life Sciences Ltd. has been selected as the inaugural recipient of the “Life Science Company of the Year” by The Biotechnology Initiative. Amorfix was selected because of its pioneering approaches to innovative diagnostic and therapeutic products for brain-wasting diseases, including Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s Disease), Parkinson’s Disease (PD) and variant Creutzfeldt-Jakob Disease (vCJD) for global markets. More
January 13, 2009
Large-Scale Testing Initiated in France with 10,000 Blood Samples Tested for vCJD
- Amorfix Demonstrates vCJD Test Can Be Used Routinely to Test Blood Donations -
Amorfix Life Sciences today announced it has tested 10,000 blood donations in France using its
EP-vCJD™ test as part of a large-scale study to demonstrate the feasibility of routine testing of blood donations for vCJD. More
December 19, 2008
Blood Test for vCJD Achieves 100% Accuracy
-
Available For Large-scale Testing of Populations to Identify Infected Carriers -
Amorfix Life Sciences today announced it achieved 100% sensitivity and 100% specificity in a second blinded trial of human blood samples using its EP-vCJD™ blood test in collaboration with the National Institute for Biological Standards and Control (NIBSC) in the United Kingdom. More
December 11, 2008
Amorfix Receives Fourth Biogen Idec Investment
- First Patent on DSE Targets Issued by United States Patent Office -
Amorfix Life Sciences announced today that Biogen Idec (Nasdaq:BIIB) made their fourth investment in Amorfix with the purchase of 254,551 shares for gross proceeds to Amorfix of US$75,000. With this investment, Biogen Idec maintains its right to license Amorfix’s superoxide dismutase-1 (SOD1) targeted therapies for use in ALS until February 10, 2009. More
November 26, 2008
Amorfix Successfully Completes ALS Drug Discovery Program
- Amorfix Also Achieves Third and Final Milestone Under Biogen Idec Agreement -
Amorfix Life Sciences announced today that it has achieved the third and final milestone under the 2006 research, investment and option agreement with Biogen Idec (Nasdaq:BIIB) to discover novel treatments for amyotrophic lateral sclerosis (ALS - Lou Gehrig’s disease). More
November 17, 2008
Amorfix Receives Third Biogen Idec Investment
- Biogen Idec Retains Option to License to Amorfix ALS Technology -
Amorfix Life Sciences announced today that Biogen Idec (Nasdaq:BIIB) made their third investment in Amorfix with the purchase of 608,250 shares for gross proceeds to Amorfix of US$150,000. With this investment, Biogen Idec maintains its right to license Amorfix’s superoxide dismutase-1 (SOD1) targeted therapies for use in ALS. More
November 6, 2008
Amorfix Announces Fiscal 2009 Second Quarter Results
Amorfix Life Sciences today announced its operational and financial results for the three and six months ended September 30, 2008. More
October 20, 2008
Amorfix is First Company in World to Show Preclinical Efficacy Using Monoclonal Anitbodies Targeting Misfolded Regions of Disease-Causing Proteins
- Amorfix Also Achieves Second Milestone Under Biogen Idec Agreement -
Amorfix Life Sciences announced today that its Disease Specific Epitope (DSE) monoclonal antibody treatments demonstrated statistically significant improvement in survival over controls in a mouse model of Amyotrophic Lateral Sclerosis (ALS). More
October 17, 2008
Amorfix vCJD Assay Achieves 100% Sensitivity and 100% Specificity on 1,000 Fresh Samples from UK Blood Donors
Amorfix Life Sciences today announced the best sensitivity and specificity ever reported using its EP-vCJD TM Blood Screening Assay to test fresh blood plasma samples from anonymous UK blood donors. Amorfix completed this testing in the laboratories of the National Institute for Biological Standards and Control (NIBSC) in the United Kingdom. More
October 8, 2008
Amorfix Sheep Scrapie Results from Blinded Panels Presented at International Prion Conference
Amorfix Life Sciences today announced that Dr. Neil Cashman, Chief Scientific Officer of Amorfix, will present a poster describing the sheep scrapie results from two blinded sheep scrapie panels using Amorfix’s prototype EP-TSE™ Blood Screening Assay at the Prion 2008 Conference today in Madrid, Spain. The presentation entitled, “Detection of prions in blood from asymptomatic scrapie sheep using Epitope Protection technology” highlights the sensitivity and specificity of the EP-TSE™ sheep scrapie assay. More
September 23, 2008
Amorfix Sets Up vCJD Blood Screening Assay in UK and Begins to Test Blood Donor Samples
Amorfix Life Sciences announced today it has set up the EP-vCJD™ assay system in the Prion Laboratory at the British National Institute for Biological Standards and Control (NIBSC) and has begun to test fresh human blood samples as part of the ongoing assay validation process announced earlier this year. More
September 12, 2008
Amorfix Reports New Finding for vCJD Blood Screening Assay and Provides Corporate Update
Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases,
today reported that its EP-vCJD™ Blood Screening Assay can detect sporadic Creutzfeldt-Jakob Disease (sCJD) prions using brain material spiked into human plasma at the same sensitivity. More
September 9, 2008
Amorfix Provides Corporate Update on Regulatory Process
and Manufacturing for vCJD Diagnostic
Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced an update on the regulatory process in the European Union (EU) and manufacturing for vCJD blood screening tests. More
August 19, 2008
Amorfix to Set Up vCJD Assay in UK to Continue Validation Process
Amorfix Life Sciences
announced today that it will set up the EP-vCJD™ assay system in the Prion Laboratory at the British National Institute for Biological Standards and Controls (NIBSC) outside London and begin to test fresh human blood samples as part of the ongoing assay validation process announced earlier this year. Based on the performance of its EP-vCJD™ assay, Amorfix received and accepted an invitation from the British government to further qualify the specificity of the assay using British blood donor samples to be supplied by the National Blood Service. More
August 7, 2008
Amorfix Announces Fiscal 2009 First Quarter Results
Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced its operational and financial results for the three months ended June 30, 2008. More
July 22, 2008
Amorfix and Dr. Cashman Receive Canadian Government Grant
to Develop Treatments for Alzheimer's Disease
Amorfix Life Sciences and the University of British Columbia (UBC), today announced a research collaboration to develop Alzheimer’s treatments based upon the discovery of misfolded superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer’s Disease. More
July 8, 2008
Amorfix Provides Corporate Update on ALS Therapeutic Program
Amorfix Life Sciences today announced that its therapy program for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig’s disease, is on schedule for completion of antibody infusion studies this fall. More
June 24, 2008
Amorfix Acheives Target Sensitivity with its Alzheimer’s Disease Diagnostic Test
Amorfix Life Sciences today announced that its diagnostic test for the presence of aggregated Abeta in Alzheimer’s disease is ready to be applied to patient samples. The company has adapted its test to specifically detect aggregated Abeta protein (amyloid) in femtogram quantities (ten parts per trillion) from an Alzheimer’s brain when it is spiked into plasma or cerebral spinal fluid (CSF). More
June 13 , 2008
Amorfix Announces 2008 Year End Results
More
May 16, 2008
Amorfix to Webcast Presentation at the Rodman & Renshaw
5th Annual Global Healthcare Conference
Amorfix Life Sciences Ltd. today announced that Dr. George Adams, President and CEO, will present a company overview at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo, Monaco.
The presentation will take place at 3:10pm local time (9:10am ET) on Monday, May 19th, 2008. A live webcast of the presentation can be accessed here. The presentation will be available for replay following the webcast. More
April 29, 2008
Amorfix Detects Scrapie Prions in Blood from Asymptomatic Sheep
Amorfix Life Sciences annouced today the detection of endogenous prions in the blood plasma of asymptomatic scrapie infected sheep. The company had previously reported detecting symptomatic sheep which was a requirement for testing of human vCJD in the United Kingdom. Scrapie, a disease in sheep similar to mad cow disease, is endemic in almost all the flocks of the 1 billion sheep in the world. Europe and North America have had programs to eradicate scrapie for many years and still have scrapie-infected herds. There were 76 newly-infected flocks in the United States in 2007. More
February 11, 2008
Amorfix Presents Results from British Blinded Panel of Spiked Human Blood Samples
Amorfix Life Sciences presented today the decoded results of a blinded panel of spiked human blood samples, tested by Amorfix’s EP-vCJDTM assay, at the 12th Annual Transmissible Spongiform Encephalopathies international conference. The samples had been provided by the British National Institute for Biological Standards and Control (NIBSC). More
February 8, 2008
Amorfix Releases Third Quarter Fiscal 2008 Results
More
February 1, 2008
UK Government Clarifies Process to Verify a Blood Test for vCJD and Releases Amorfix B Panel Results
Amorfix Life Sciences announced today that the Expert Advisory Group of the British National Institute for Biological Standards and Controls (NIBSC) has now established the process to verify the performance of an acceptable blood test for vCJD. Based on the performance of its EP-vCJD™ assay, Amorfix received and accepted an invitation from the British government to further qualify the assay using British blood samples. The NIBSC will provide blood samples from scrapie-infected sheep, normal human controls and patients with vCJD. More
January 10, 2008
Amorfix is Now a Member of the European Diagnostic Manufacturers Association
View EDMA's Press Release
January 4, 2008
Amorfix Appoints Aziz Mekouar as a Member of Board of Directors
Amorfix is pleased to announce the appointment of Aziz Mekouar to the company’s Board of Directors. “We are delighted to welcome Mr. Mekouar to our Board,” said Graham Strachan, Chair of the Board of Amorfix. “His substantial business experience and leadership in global affairs and with the United Nations will be an important asset as Amorfix continues to pursue its strategic objective of becoming a world leader in the treatment and diagnosis of misfolded-protein and prion diseases." More
|
